BioSpace News Archive

Business

Marker Therapeutics Announces Comprehensive Non-Dilutive Agreement With CellReady™

Marker Therapeutics, Inc. today announced that it has entered into a comprehensive agreement with CellReady™, a newly formed Contract Development and Manufacturing Organization (CDMO) founded by John Wilson, founder and CEO of Wilson Wolf Corporation and Marker Co-Founder and Board Member.

May 1, 2023
·
9 min read
Drug Development

Atsena Therapeutics Receives FDA Clearance of IND Application for ATSN-201, an Investigational Gene Therapy for the Treatment of X-linked Retinoschisis

Atsena Therapeutics today announced the U.S. ood and Drug Administration (FDA) has cleared the company’s Investigational New Drug (IND) application for a Phase I/II clinical trial of ATSN-201 in patients with X-linked retinoschisis (XLRS).

May 1, 2023
·
4 min read
Genetown

Ardelyx Announces Additional Data Supporting First-In-Class IBSRELA® (tenapanor) for Adults with IBS-C, to be Presented at the 2023 Digestive Disease Week Conference

Ardelyx, Inc. announced that additional data supporting the efficacy and safety of IBSRELA will be presented in a poster at the 2023 Digestive Disease Week Conference to be held May 6-9, 2023, in Chicago, Illinois.

May 1, 2023
·
5 min read
Pharm Country

VYNE Therapeutics Announces Selection of Development Candidate VYN202, a Potential Best-in-Class Oral Small Molecule BD2-Selective BET Inhibitor for the Treatment of Immuno-Inflammatory Conditions

VYNE Therapeutics Inc. announced the selection of a development candidate for its oral BD2-selective bromodomain and extra-terminal inhibitor program, VYN202, for the treatment of immuno-inflammatory conditions.

May 1, 2023
·
7 min read
BioMidwest

OrthoPediatrics Corp. Continues Leading Sponsorship at 2023 POSNA Annual Meeting

OrthoPediatrics Corp. a company focused exclusively on advancing the field of pediatric orthopedics, announced its continued support of the 2023 Pediatric Orthopaedic Society of North America annual meeting this week in Nashville, Tennessee.

May 1, 2023
·
2 min read
Biotech Beach

Erasca Granted FDA Fast Track Designation for CNS-Penetrant EGFR Inhibitor ERAS-801 in Patients with Glioblastoma

Erasca, Inc. (Nasdaq: ERAS) today announced the United States Food and Drug Administration (FDA) has granted Fast Track Designation (FTD) to ERAS-801 for the treatment of adult patients with glioblastoma (GBM) with epidermal growth factor receptor (EGFR) gene alterations.

May 1, 2023
·
7 min read
Business

Immatics Announces First Bristol Myers Squibb Opt-in of TCR-T Candidate from Ongoing Multi-target Strategic Collaboration

Immatics N.V. (NASDAQ: IMTX, “Immatics”) today announced that Bristol Myers Squibb (NYSE:BMY) has exercised its option and entered into an exclusive worldwide license for the first T cell receptor engineered T cell therapy (TCR-T) candidate from their ongoing collaboration.

May 1, 2023
·
4 min read
Genetown

Minerva Neurosciences Announces the NDA Filing for Roluperidone for the Treatment of Negative Symptoms in Schizophrenia FDA grants appeal and files NDA

Minerva Neurosciences, Inc. today announced that the U.S. Food and Drug Administration (FDA) filed the Company’s New Drug Application (NDA) for roluperidone for the treatment of negative symptoms in patients with schizophrenia on April 27, 2023.

May 1, 2023
·
5 min read
Biotech Beach

Eledon Pharmaceuticals Announces up to $185 Million Financing to Advance Tegoprubart Kidney Transplantation Clinical Trials

Eledon Pharmaceuticals, Inc. today announced that it has entered into a definitive securities purchase agreement with certain healthcare investors that will provide up to $185 million in gross proceeds to Eledon through a private placement.

May 1, 2023
·
6 min read
Deals

ACELYRIN, INC. Announces Launch of IPO Roadshow

ACELYRIN, INC. today announced it has launched a roadshow for an initial public offering (IPO) of 20,600,000 shares of its common stock.

May 1, 2023
·
2 min read